{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13"],"submitter":["Guo Y"],"pubmed_abstract":["<h4>Background</h4>Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the related factors are not well described.<h4>Methods</h4>A total of 112 patients who achieved PEG-IFN-induced HBsAg loss were recruited. HBV biomarkers and biochemical parameters were examined dynamically. HBV RNA levels were assessed in the cross-sectional analysis. The primary endpoint was HRV, defined as the reappearance of HBsAg after PEG-IFN discontinuation.<h4>Results</h4>HRV occurred in 17 patients during the follow-up period. Univariable analysis indicated that hepatitis B e antigen (HBeAg) status, different levels of hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) at the end of PEG-IFN treatment (EOT) were significantly associated with the incidence of HRV through using the log-rank test. Additionally, time-dependent receiver operating characteristic (ROC) analysis showed that the anti-HBs was superior to anti-HBc in predictive power for the incidence of HRV during the follow-up period. Multivariable Cox proportional hazard analysis found that anti-HBs ≥1.3 log<sub>10</sub>IU/L (hazard ratio (HR), 0.148; 95% confidence interval (CI), 0.044-0.502) and HBeAg negativity (HR, 0.183; 95% CI, 0.052-0.639) at EOT were independently associated with lower incidence of HRV. Cross-sectional analysis indicated that the HBV RNA levels were significantly correlated with the HBsAg levels in patients with HRV (r=0.86, p=0.003).<h4>Conclusions</h4>EOT HBeAg negativity and anti-HBs ≥1.3 log<sub>10</sub>IU/L identify the low risk of HRV after PEG-IFN discontinuation."],"journal":["Frontiers in cellular and infection microbiology"],"pagination":["1120300"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9998526"],"repository":["biostudies-literature"],"pubmed_title":["End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation."],"pmcid":["PMC9998526"],"pubmed_authors":["Guo Y","He J","Zhang J","Li F","Mao R","Lin Y","Zhu H","Yang F","Shen Z","Zhang Y","Jin C","Han J","Chen S"],"additional_accession":[]},"is_claimable":false,"name":"End-of-treatment anti-HBs levels and HBeAg status identify durability of HBsAg loss after PEG-IFN discontinuation.","description":"<h4>Background</h4>Hepatitis B surface antigen (HBsAg) loss, namely, the functional cure, can be achieved through the pegylated interferon (PEG-IFN)-based therapy. However, it is an unignorable fact that a small proportion of patients who achieved functional cure develop HBsAg reversion (HRV) and the related factors are not well described.<h4>Methods</h4>A total of 112 patients who achieved PEG-IFN-induced HBsAg loss were recruited. HBV biomarkers and biochemical parameters were examined dynamically. HBV RNA levels were assessed in the cross-sectional analysis. The primary endpoint was HRV, defined as the reappearance of HBsAg after PEG-IFN discontinuation.<h4>Results</h4>HRV occurred in 17 patients during the follow-up period. Univariable analysis indicated that hepatitis B e antigen (HBeAg) status, different levels of hepatitis B surface antibody (anti-HBs), and hepatitis B core antibody (anti-HBc) at the end of PEG-IFN treatment (EOT) were significantly associated with the incidence of HRV through using the log-rank test. Additionally, time-dependent receiver operating characteristic (ROC) analysis showed that the anti-HBs was superior to anti-HBc in predictive power for the incidence of HRV during the follow-up period. Multivariable Cox proportional hazard analysis found that anti-HBs ≥1.3 log<sub>10</sub>IU/L (hazard ratio (HR), 0.148; 95% confidence interval (CI), 0.044-0.502) and HBeAg negativity (HR, 0.183; 95% CI, 0.052-0.639) at EOT were independently associated with lower incidence of HRV. Cross-sectional analysis indicated that the HBV RNA levels were significantly correlated with the HBsAg levels in patients with HRV (r=0.86, p=0.003).<h4>Conclusions</h4>EOT HBeAg negativity and anti-HBs ≥1.3 log<sub>10</sub>IU/L identify the low risk of HRV after PEG-IFN discontinuation.","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-04T18:51:10.481Z","creation":"2025-04-04T18:51:10.481Z"},"accession":"S-EPMC9998526","cross_references":{"pubmed":["36909726"],"doi":["10.3389/fcimb.2023.1120300"]}}